Literature DB >> 17002477

QALYs: are they helpful to decision makers?

Maurice McGregor1, J Jaime Caro.   

Abstract

The QALY is the product of life expectancy (estimated in years) and its quality over that time (estimated in utilities or QOL units). It theoretically enables direct comparison of the costs of obtaining different health outcomes through cost utility analysis (CUA). In this review, we argue that, at present, the problems related to the use of utilities preclude the use of cost per QALY as a major determinant of policy decisions on the acquisition and use of health technologies. Those who use CUA can be divided into (i) those who inform the process of decision making through CUA and (ii) those who make the decisions. The former have no direct budgetary responsibility for the decisions that are taken, while the decision makers must pay for those decisions from their budgets. Use of CUA rests on the assumption that all QALYs are of equivalent value in the eyes of society. However, the value accorded to them varies with circumstances. The utilities or QOL indices required to compute QALYs can be measured in different ways, which give different answers, and have been shown to be unreliable. Thus, the QALY is not sufficiently accurate or reliable to be used by decision makers as a basis for comparison of the costs of different technologies. Until the theoretical and practical problems of determining health preferences are resolved and the methods of their measurement are standardised, it is necessary to estimate the cost effectiveness of health interventions by relating their cost to their primary health outcomes.

Mesh:

Year:  2006        PMID: 17002477     DOI: 10.2165/00019053-200624100-00002

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  33 in total

1.  Inclusion of drugs in provincial drug benefit programs: who is making these decisions, and are they the right ones?

Authors:  Andreas Laupacis
Journal:  CMAJ       Date:  2002-01-08       Impact factor: 8.262

Review 2.  Is economic evaluation in touch with society's health values?

Authors:  Joanna Coast
Journal:  BMJ       Date:  2004-11-20

3.  End-user involvement in health technology assessment (HTA) development: a way to increase impact.

Authors:  Maurice McGregor; James M Brophy
Journal:  Int J Technol Assess Health Care       Date:  2005       Impact factor: 2.188

4.  Cost-effectiveness lessons from disease-modifying drugs in the treatment of multiple sclerosis.

Authors:  Jeffrey S Hoch
Journal:  Expert Rev Pharmacoecon Outcomes Res       Date:  2004-10       Impact factor: 2.217

5.  Valuing outcomes in health care: a comparison of willingness to pay and quality-adjusted life-years.

Authors:  M V Bala; L L Wood; G A Zarkin; E C Norton; A Gafni; B O'Brien
Journal:  J Clin Epidemiol       Date:  1998-08       Impact factor: 6.437

6.  Quality of life in epilepsy: comparison of four preference measures.

Authors:  K Stavem
Journal:  Epilepsy Res       Date:  1998-02       Impact factor: 3.045

Review 7.  Relationship between psychometric and utility-based approaches to the measurement of health-related quality of life.

Authors:  D A Revicki; R M Kaplan
Journal:  Qual Life Res       Date:  1993-12       Impact factor: 4.147

8.  Cost-effectiveness league tables: more harm than good?

Authors:  M Drummond; G Torrance; J Mason
Journal:  Soc Sci Med       Date:  1993-07       Impact factor: 4.634

9.  The cost-effectiveness of sildenafil.

Authors:  K J Smith; M S Roberts
Journal:  Ann Intern Med       Date:  2000-06-20       Impact factor: 25.391

10.  The repeatability of three methods for measuring prospective patients' values in the context of treatment choice for end-stage renal disease.

Authors:  P A Groome; T A Hutchinson; P Tousignant; J A Hanley
Journal:  J Clin Epidemiol       Date:  1999-09       Impact factor: 6.437

View more
  18 in total

1.  Regulatory benefit-risk assessment and comparative effectiveness research: strangers, bedfellows or strange bedfellows?

Authors:  Louis P Garrison
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

2.  Evaluation of benefit-risk.

Authors:  Silvio Garattini
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

3.  Should we abandon QALYs as a resource allocation tool?

Authors:  Sandeep Vijan
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

4.  Lessons from trial-based cost-effectiveness analyses of mental health interventions: why uncertainty about the outcome, estimate and willingness to pay matters.

Authors:  Jeffrey S Hoch; Carolyn S Dewa
Journal:  Pharmacoeconomics       Date:  2007       Impact factor: 4.981

5.  Cost-effectiveness modeling of abatacept versus other biologic agents in DMARDS and anti-TNF inadequate responders for the management of moderate to severe rheumatoid arthritis.

Authors:  Anthony Russell; Ariel Beresniak; Louis Bessette; Boulos Haraoui; Proton Rahman; Carter Thorne; Ross Maclean; Danielle Dupont
Journal:  Clin Rheumatol       Date:  2008-12-17       Impact factor: 2.980

6.  Methods of economic evaluation for the German statutory healthcare system.

Authors:  J Jaime Caro
Journal:  Pharmacoeconomics       Date:  2009       Impact factor: 4.981

7.  A comparison of the superficial inferior epigastric artery flap and deep inferior epigastric perforator flap in postmastectomy reconstruction: A cost-effectiveness analysis.

Authors:  Achilleas Thoma; Leigh Jansen; Sheila Sprague; Eric Duku P Stat
Journal:  Can J Plast Surg       Date:  2008

8.  The use of QALY weights for QALY calculations: a review of industry submissions requesting listing on the Australian Pharmaceutical Benefits Scheme 2002-4.

Authors:  Paul A Scuffham; Jennifer A Whitty; Andrew Mitchell; Rosalie Viney
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

Review 9.  Current challenges in health economic modeling of cancer therapies: a research inquiry.

Authors:  Jeffrey D Miller; Kathleen A Foley; Mason W Russell
Journal:  Am Health Drug Benefits       Date:  2014-05

10.  Users' guide to the orthopaedic literature: what is a cost-effectiveness analysis?

Authors:  Stephanie Tanner; Sheila Sprague; Kyle Jeray
Journal:  Indian J Orthop       Date:  2008-04       Impact factor: 1.251

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.